U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT07572825) titled 'Assessing the Safety and Tolerability of NMN in DHDDS-CDG' on May 01.
Brief Summary: The primary objective of this study is to evaluate the safety and tolerability of the dietary supplement, nicotinamide mononucleotide (NMN), in individuals with dehydrodolichol diphosphate synthase congenital disorder of glycosylation (DHDDS-CDG). This will to contribute to knowledge that will allow healthcare providers to make informed decisions about recommending this dietary supplement in this population.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
DHDDS-Congenital Disorder of Glycosylation
DHDDS-CDG
Congenital Disorder of G...